These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2625371)

  • 1. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
    Debruyne D; Gram LF; Grollier G; Camsonne R; Agron L; Dao MT; Lacotte J; Bigot MC; Moulin M
    Int J Clin Pharmacol Res; 1989; 9(5):319-25. PubMed ID: 2625371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.
    Turgeon J; Fiset C; Giguère R; Gilbert M; Moerike K; Rouleau JR; Kroemer HK; Eichelbaum M; Grech-Bélanger O; Bélanger PM
    J Pharmacol Exp Ther; 1991 Nov; 259(2):789-98. PubMed ID: 1941626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
    Wensing G; Hoffmann K; Heidemann HT
    Z Gastroenterol; 1993 Jan; 31(1):15-9. PubMed ID: 8447150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination].
    Soto Alvarez J; Alsar Ortiz MJ
    Rev Clin Esp; 1993 Jun; 193(2):60-3. PubMed ID: 8341815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
    Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranitidine disposition in severe hepatic cirrhosis.
    Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone and enzyme induction in patients with alcoholic cirrhosis.
    Miguet JP; Vuitton D; Thebault-Lucas A; Joanne C; Dhumeaux D
    Gastroenterology; 1980 May; 78(5 Pt 1):996-1000. PubMed ID: 7380205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temazepam clearance unaltered in cirrhosis.
    Ochs HR; Greenblatt DJ; Verburg-Ochs B; Matlis R
    Am J Gastroenterol; 1986 Jan; 81(1):80-4. PubMed ID: 2867675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading.
    Fromm MF; Darbar D; Dell'Orto S; Roden DM
    J Pharmacol Exp Ther; 1999 Jul; 290(1):253-8. PubMed ID: 10381784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal metabolism of morphine in cirrhosis.
    Patwardhan RV; Johnson RF; Hoyumpa A; Sheehan JJ; Desmond PV; Wilkinson GR; Branch RA; Schenker S
    Gastroenterology; 1981 Dec; 81(6):1006-11. PubMed ID: 7286578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
    Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
    Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
    Funck-Brentano C; Turgeon J; Woosley RL; Roden DM
    J Pharmacol Exp Ther; 1989 Apr; 249(1):134-42. PubMed ID: 2496225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver function and medroxyprogesterone acetate elimination in man.
    Rautio A
    Biomed Pharmacother; 1984; 38(4):199-204. PubMed ID: 6498308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic studies of quinidine in patients with arrhythmias.
    Conrad KA; Molk BL; Chidsey CA
    Circulation; 1977 Jan; 55(1):1-7. PubMed ID: 830196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
    Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
    Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colchicine clearance is impaired in alcoholic cirrhosis.
    Leighton JA; Bay MK; Maldonado AL; Schenker S; Speeg KV
    Hepatology; 1991 Dec; 14(6):1013-5. PubMed ID: 1959847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.
    Ayesh R; Dawling S; Hayler A; Oates NS; Cholerton S; Widdop B; Idle JR; Smith RL
    Chirality; 1991; 3(1):14-8. PubMed ID: 2039678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects.
    Preiss R; Matthias M; Sohr R; Brockmann B; Hüller H
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S79-88. PubMed ID: 3842695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impairment of drug elimination in patients with liver disease.
    Narang AP; Datta DV; Mathur VS
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
    von Mandach U; Jost G; Preisig R
    Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.